JP2018529635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529635A5 JP2018529635A5 JP2018501182A JP2018501182A JP2018529635A5 JP 2018529635 A5 JP2018529635 A5 JP 2018529635A5 JP 2018501182 A JP2018501182 A JP 2018501182A JP 2018501182 A JP2018501182 A JP 2018501182A JP 2018529635 A5 JP2018529635 A5 JP 2018529635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 214
- 239000012634 fragment Substances 0.000 claims description 202
- 239000000427 antigen Substances 0.000 claims description 201
- 102000036639 antigens Human genes 0.000 claims description 201
- 108091007433 antigens Proteins 0.000 claims description 201
- 102100037632 Progranulin Human genes 0.000 claims description 26
- 101710114165 Progranulin Proteins 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 8
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100032889 Sortilin Human genes 0.000 description 20
- 108010014657 sortilin Proteins 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 101000868139 Homo sapiens Sortilin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021151783A JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1512215.3 | 2015-07-13 | ||
| GBGB1512215.3A GB201512215D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| PCT/EP2016/066516 WO2017009327A1 (en) | 2015-07-13 | 2016-07-12 | Antibodies that bind to sortilin and inhibit the binding of progranulin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021151783A Division JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529635A JP2018529635A (ja) | 2018-10-11 |
| JP2018529635A5 true JP2018529635A5 (enExample) | 2019-08-15 |
| JP6979397B2 JP6979397B2 (ja) | 2021-12-15 |
Family
ID=54013862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501182A Active JP6979397B2 (ja) | 2015-07-13 | 2016-07-12 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
| JP2021151783A Pending JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021151783A Pending JP2022003058A (ja) | 2015-07-13 | 2021-09-17 | ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 |
Country Status (35)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| ES2940311T3 (es) | 2018-07-13 | 2023-05-05 | Alector Llc | Anticuerpos anti-sortilina y métodos de uso de los mismos |
| EP3666281A1 (en) * | 2018-12-14 | 2020-06-17 | Insusense ApS | Compositions comprising sortilin-1 |
| JP2023507846A (ja) * | 2019-12-23 | 2023-02-27 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン変異体 |
| EP4171743A4 (en) | 2020-06-24 | 2024-07-24 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
| KR20250028349A (ko) | 2022-06-23 | 2025-02-28 | 드라우프니르 바이오 에이피에스 | 리소좀 내 세포외 표적의 분해를 선택적으로 유도하는 이작용성 분자 |
| CN118496354A (zh) * | 2023-02-15 | 2024-08-16 | 三优生物医药(上海)有限公司 | 包含共同轻链的抗体库、其制备方法及其用途 |
| WO2025031098A1 (zh) * | 2023-08-09 | 2025-02-13 | 瑞诺元(苏州)生物科技有限公司 | 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用 |
| WO2025132764A1 (en) * | 2023-12-21 | 2025-06-26 | Amylonix Ab | A sortilin-binding polypeptide |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| PT1150918E (pt) | 1999-02-03 | 2005-01-31 | Biosante Pharmaceuticals Inc | Metodo de fabrico de particulas terapeuticas de fosfato de calcio |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| WO2002043478A2 (en) | 2000-11-30 | 2002-06-06 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| ATE545429T1 (de) | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
| BRPI0619056A2 (pt) | 2005-11-28 | 2011-09-20 | Genmab As | anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica |
| US20100028333A1 (en) | 2006-12-15 | 2010-02-04 | Getty Krista L | Receptor for amyloid beta and uses thereof |
| LT2120997T (lt) | 2006-12-21 | 2017-06-26 | H. Lundbeck A/S | Proneurotropinų veiklos moduliavimas |
| EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
| EP2274327B1 (en) | 2008-04-27 | 2019-03-27 | H. Lundbeck A/S | Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin |
| US8420784B2 (en) | 2008-05-27 | 2013-04-16 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor, (IL-10R) antibodies |
| WO2010022175A1 (en) | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| EP3165537A1 (en) * | 2008-12-19 | 2017-05-10 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| RU2536232C2 (ru) * | 2011-07-01 | 2014-12-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| JP6239635B2 (ja) | 2012-11-02 | 2017-11-29 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 血管石灰化の誘導因子であるソルチリン１ |
| CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| ES2940311T3 (es) | 2018-07-13 | 2023-05-05 | Alector Llc | Anticuerpos anti-sortilina y métodos de uso de los mismos |
-
2015
- 2015-07-13 GB GBGB1512215.3A patent/GB201512215D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0141A patent/JO3710B1/ar active
- 2016-07-12 BR BR112018000771-4A patent/BR112018000771A2/pt not_active IP Right Cessation
- 2016-07-12 CR CR20180002A patent/CR20180002A/es unknown
- 2016-07-12 EP EP16739087.1A patent/EP3322726B1/en active Active
- 2016-07-12 PE PE2018000064A patent/PE20181014A1/es unknown
- 2016-07-12 RU RU2018100824A patent/RU2735639C2/ru active
- 2016-07-12 CN CN201680040476.5A patent/CN107849135A/zh active Pending
- 2016-07-12 AU AU2016292980A patent/AU2016292980B2/en active Active
- 2016-07-12 WO PCT/EP2016/066516 patent/WO2017009327A1/en not_active Ceased
- 2016-07-12 MX MX2018000506A patent/MX2018000506A/es unknown
- 2016-07-12 US US15/207,880 patent/US10428147B2/en active Active
- 2016-07-12 KR KR1020187001192A patent/KR102778576B1/ko active Active
- 2016-07-12 US US15/743,549 patent/US10479835B2/en active Active
- 2016-07-12 CA CA2989739A patent/CA2989739A1/en active Pending
- 2016-07-12 CN CN202210124751.9A patent/CN114478774A/zh active Pending
- 2016-07-12 UA UAA201800574A patent/UA125136C2/uk unknown
- 2016-07-12 TW TW105121903A patent/TWI760305B/zh not_active IP Right Cessation
- 2016-07-12 ES ES16739087T patent/ES3024469T3/es active Active
- 2016-07-12 JP JP2018501182A patent/JP6979397B2/ja active Active
- 2016-07-12 EA EA201890038A patent/EA201890038A1/ru unknown
- 2016-07-12 CN CN202210124752.3A patent/CN114478775A/zh active Pending
- 2016-07-12 AR ARP160102109A patent/AR105335A1/es not_active Application Discontinuation
- 2016-07-12 TN TNP/2017/000534A patent/TN2017000534A1/en unknown
- 2016-07-12 MA MA42440A patent/MA42440B1/fr unknown
- 2016-07-12 RS RS20250507A patent/RS66856B1/sr unknown
- 2016-07-12 PL PL16739087.1T patent/PL3322726T3/pl unknown
- 2016-07-12 HU HUE16739087A patent/HUE071424T2/hu unknown
- 2016-07-12 HR HRP20250602TT patent/HRP20250602T1/hr unknown
-
2017
- 2017-12-18 ZA ZA2017/08613A patent/ZA201708613B/en unknown
- 2017-12-18 CO CONC2017/0012988A patent/CO2017012988A2/es unknown
- 2017-12-22 IL IL256503A patent/IL256503B/en unknown
-
2018
- 2018-01-11 NI NI201800007A patent/NI201800007A/es unknown
- 2018-01-11 PH PH12018500100A patent/PH12018500100A1/en unknown
- 2018-01-11 DO DO2018000014A patent/DOP2018000014A/es unknown
- 2018-01-11 CL CL2018000092A patent/CL2018000092A1/es unknown
- 2018-01-11 SV SV2018005613A patent/SV2018005613A/es unknown
- 2018-01-12 EC ECIEPI20182725A patent/ECSP18002725A/es unknown
-
2019
- 2019-07-24 US US16/521,279 patent/US10889650B2/en active Active
-
2020
- 2020-09-24 CL CL2020002468A patent/CL2020002468A1/es unknown
- 2020-11-13 US US17/097,457 patent/US11548950B2/en active Active
-
2021
- 2021-09-17 JP JP2021151783A patent/JP2022003058A/ja active Pending
-
2022
- 2022-11-18 US US18/057,104 patent/US12331123B2/en active Active
-
2025
- 2025-05-16 US US19/210,142 patent/US20250277040A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529635A5 (enExample) | ||
| US12496342B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| KR102365871B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| AU2012347972B2 (en) | PDGF receptor beta binding polypeptides | |
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| JP6779012B2 (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| JP2019527194A5 (enExample) | ||
| TW201641516A (zh) | 抗-ｉｌ-２３抗體 | |
| JP2017536354A (ja) | 抗プロ／潜在型−ミオスタチン抗体およびその使用 | |
| TW201406391A (zh) | 抗－ｉｌ－２３抗體 | |
| JP2020527152A5 (enExample) | ||
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| JP2021506325A (ja) | Ｃｄ２２に結合する重鎖抗体 | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| EP3454901A1 (en) | Compositions and methods for treating spinal muscular atrophy | |
| JP2013508292A5 (enExample) | ||
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| DE112019003835T5 (de) | Arzneimittel zur verwendung bei der behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung sowie verfahren zur behandlung oder vorbeugung einer mit c5 in zusammenhang stehenden erkrankung | |
| US20240101674A1 (en) | Pd1 and vegfr2 dual-binding agents | |
| EP3487531A1 (en) | Compositions and methods for treating frontotemporal dementia | |
| WO2019169015A1 (en) | Anti cd6 antibodies for treating severe asthma | |
| US20220041694A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| JP2023545075A (ja) | ＣＤ１ａ抗体およびその使用 | |
| JP6811186B2 (ja) | イヌ血管内皮成長因子へ結合する抗体およびイヌ血管新生関連疾患の処置におけるその使用 |